Drug Information

Drug General Information
Drug ID
D0N3SR
Former ID
DCL000288
Drug Name
Cilnidipine
Synonyms
Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Drug Type
Small molecular drug
Indication High blood pressure [ICD9: 401; ICD10:I10-I16] Phase 3 [524770], [542719]
Company
Fuji Viscera Pharmaceutical
Structure
Download
2D MOL

3D MOL
Formula
C27H28N2O7
InChI
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
InChIKey
KJEBULYHNRNJTE-DHZHZOJOSA-N
CAS Number
CAS 132203-70-4
PubChem Compound ID
5282138
PubChem Substance ID
7848236, 8616904, 12014042, 14786166, 24892414, 26755677, 39315632, 50032253, 50111041, 53790108, 57358530, 75371776, 81092904, 85174238, 85789106, 90341030, 91611858, 92308863, 92712170, 93165423, 99437240, 103587541, 104063686, 113856514, 117867117, 121361210, 124757149, 125163953, 126625786, 126655763, 126656883, 126665639, 131480839, 131840712, 134338944, 135025896, 135692096, 135698202, 135727151, 136367386, 137231387, 137349403, 144205554, 160849806, 162037539, 162177503, 163388008, 163564376, 163621080, 163686403
SuperDrug ATC ID
C08CA14
Target and Pathway
Target(s) Voltage-dependent L-type calcium channel Target Info Blocker [534852], [535452]
Voltage-dependent N-type calcium channel Target Info Blocker [534852], [535452]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Synaptic vesicle cycle
Retrograde endocannabinoid signaling
Cholinergic synapse
Serotonergic synapse
GABAergic synapse
Dopaminergic synapse
Taste transduction
Type II diabetes mellitus
Morphine addiction
Nicotine addiction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group II pathway
Thyrotropin-releasing hormone receptor signaling pathway
Endogenous cannabinoid signaling
GABA-B receptor II signaling
Reactome Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
WikiPathways Calcium Regulation in the Cardiac Cell
Synaptic Vesicle Pathway
References
Ref 524770ClinicalTrials.gov (NCT02145104) Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension. U.S. National Institutes of Health.
Ref 542719(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7767).
Ref 534852Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.
Ref 535452N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.